Skip to content

research

Articles tagged with “research

25 articles
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects article visual for Low Dose Ketamine

Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects

Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.

Read
news

FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality

The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.

news

Trump EO on Psychedelics: What It Means for Ketamine

President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.

news

Glutamate Pathway Treatments Reshape TRD Care in 2026

A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.

research

Ketamine and Immune Function: Immunomodulatory Effects of Low-Dose Ketamine

A research-focused review of ketamine's effects on the immune system, including its impact on innate and adaptive immunity, inflammatory cytokines, immune cell function, and implications for patients with autoimmune conditions and chronic inflammation.

research

Ketamine and the Gut-Brain Axis: How the Microbiome Influences Treatment Response

An in-depth look at the emerging research connecting ketamine therapy to the gut-brain axis, including how gut microbiome composition may predict and modulate ketamine's antidepressant and analgesic effects.

research

Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons

Review five low-dose ketamine composite case studies, including depression, PTSD, CRPS, bipolar depression, and suicidal ideation, with research-backed clinical lessons.

research

How to Start a Ketamine Therapy Practice: A Clinician's Guide

A clinician guide to starting a ketamine therapy practice, covering registration, state review, protocols, monitoring, compounding, documentation, staffing, and referrals.

research

The Complete Guide to Low-Dose Ketamine Therapy

A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.

research

What Is the Response Rate for Ketamine Therapy?

Approximately 50 to 70 percent of patients with treatment-resistant depression respond to a course of low-dose ketamine infusions.

research

Ketamine and Neuroinflammation: How Anti-Inflammatory Effects Support Mental Health

Ketamine lowers inflammatory cytokines and calms microglia, effects that support its antidepressant action alongside biomarker and questionnaire monitoring.

research

Biomarkers for Predicting Ketamine Treatment Response

A review of emerging biological markers that may predict which patients will respond to ketamine therapy, including inflammatory markers, neuroimaging signatures, genetic polymorphisms, and electrophysiological features.

research

Sex Differences in Ketamine Treatment Response: Hormonal and Genetic Factors

What research says about sex differences in ketamine treatment response, including hormones, genetics, dosing questions, and the limits of current clinical evidence.

research

Glutamate System Modulation by Low-Dose Ketamine

Glutamate system modulation by low-dose ketamine works through NMDA receptor blockade, an AMPA-driven glutamate surge, and BDNF-linked plasticity.

research

Ketamine Effects on Sleep Architecture: Slow-Wave Sleep and REM Changes

How does low-dose ketamine affect sleep? Review of slow-wave sleep enhancement, REM modulation, and links between sleep architecture and antidepressant action.

research

Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines

Learn how telehealth ketamine marketing can address off-label use, FTC health claims, DEA telemedicine rules, REMS distinctions, and state-specific review needs.

research

Anti-Inflammatory Properties of Low-Dose Ketamine: Cytokine Modulation

Low-dose ketamine lowers IL-6 and TNF-alpha via NF-kappaB inhibition. See how cytokine modulation shapes its antidepressant and pain effects.

research

BDNF Signaling and Ketamine's Antidepressant Action

A detailed examination of how ketamine activates brain-derived neurotrophic factor signaling, TrkB receptor pathways, and the mTOR cascade to produce rapid antidepressant effects. Covers molecular mechanisms, clinical evidence, and implications for personalized treatment.

research

Neuroplasticity Mechanisms in Ketamine Therapy

An in-depth exploration of how low-dose ketamine promotes neural rewiring, synaptogenesis, and dendritic spine formation. This article examines the molecular and cellular pathways through which ketamine restores synaptic connectivity in mood and pain disorders.

research

Ketamine-Opioid System Interactions: Naltrexone Studies and Debate

How ketamine interacts with opioid receptors, what the naltrexone blockade study found, and what it means for patients on opioid medications.

research

Ketamine and the Default Mode Network: Neuroimaging Evidence

How does ketamine affect the brain's default mode network? A review of fMRI, MEG, and PET studies on DMN connectivity, depression, and treatment response.

research

Low-Dose Ketamine for Acute Suicidal Ideation: Clinical Evidence

A review of the clinical trial evidence examining low-dose ketamine as an intervention for acute suicidal ideation. This article evaluates randomized controlled trials, naturalistic studies, and emergency department protocols demonstrating ketamine's rapid anti-suicidal effects.

research

Ketamine, Neuroplasticity, and Brain-Derived Neurotrophic Factor

How does low-dose ketamine drive neuroplasticity? A look at BDNF release, TrkB and mTOR activation, and the synapse rebuilding behind its rapid antidepressant effect.

research

Meta-Analyses of Low-Dose Ketamine for Treatment-Resistant Depression

Meta-analyses of low-dose ketamine for treatment-resistant depression show large 24-hour effects and better durability for racemic ketamine than esketamine.

research

Rapid-Onset Antidepressant Mechanisms of Low-Dose Ketamine

Low-dose ketamine's rapid-onset antidepressant mechanisms explain why relief begins in hours, not weeks, via NMDA blockade and BDNF-driven synaptic growth.

Contact Low Dose Ketamine

Send corrections, provider questions, or advertising inquiries.